Meeting
2016 Genitourinary Cancers Symposium
Sequencing of treatments in metastatic CRPC for patients who have completed all therapeutic interventions.
Authors
Allie E. Steinberger
Tulane University School of Medicine, New Orleans, LA
Allie E. Steinberger , Elisa M. Ledet , Allison H. Feibus , Vikram J. Premkumar , Aryeneesh Dotiwala , Michael D. Stolten , Brian E. Lewis , A. Oliver Sartor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 339)
DOI
10.1200/jco.2016.34.2_suppl.339
Abstract #
339
Poster Bd #
E1
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry.
First Author: Edoardo Francini
Poster
2019 Genitourinary Cancers Symposium
Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC).
First Author: Cecile Vicier
Poster
2023 ASCO Annual Meeting
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
First Author: Alicia K. Morgans
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian